Combination lumacaftor and ivacaftor therapy for cystic fibrosis

Expert Opinion on Orphan Drugs

Volumn 4, Issue 2, 2016, Pages 233-242

  McColley, Susanna A ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

Cystic fibrosis; cystic fibrosis transmembrane conductance regulator; ivacaftor; lumacaftor; VX 770; VX 809

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; GLUCOSE; IVACAFTOR; LIVER ENZYME; LUMACAFTOR;

ABDOMINAL PAIN; ACNE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CREATINE KINASE BLOOD LEVEL; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ERYTHEMA; FATIGUE; FLATULENCE; GENE MUTATION; GLUCOSE BLOOD LEVEL; HOMOZYGOTE; HUMAN; INFLUENZA; LUNG FUNCTION; MEDLINE; MUSCULOSKELETAL CHEST PAIN; MYALGIA; NAUSEA; NOSE OBSTRUCTION; OROPHARYNX PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RHINITIS; RHINOPHARYNGITIS; RHINORRHEA; SIDE EFFECT; SINUS CONGESTION; SINUS HEADACHE; UPPER RESPIRATORY TRACT INFECTION; WHEEZING;

EID: 84958630937     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2016.1133282     Document Type: Article

References (32)

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005; 352: 1992-2001.
2. Schechter MS. Nongenetic influences on cystic fibrosis outcomes. Curr Opin Pulm Med. 2011; 17: 448-454.
3. De Boeck K, Kent L, Davies J, et al. CFTR biomarkers: time for promotion to surrogate end-point. Eur Respir J. 2013; 41: 203-216.
4. Cystic Fibrosis Foundation Patient Data Registry Report. 2015. [cited 2015 Sep 29]. Available from: www.cff.org/livingwithcf/qualityimprovement/patientdataregistryreport
5. Mogayzel PJ Jr, Naureckas ET, Robinson KA,, Mueller G. et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013; 187: 680-689.
6. Sawicki GS, Tiddens H. Managing treatment complexity in cystic fibrosis: challenges and opportunities. Pediatr Pulmonol. 2012; 47: 523-533.
7. Modi AC, Lim CS, Yu N, et al. A multi-method assessment of treatment adherence for children with cystic fibrosis. Journal of Cystic Fibrosis. 2006; 5: 177-185.
8. ClinicalTrials.gov. A service of the National Institutes of Health. [cited 17 October 2015]. Available from: http://www.clinicaltrials.gov/ct2/results?term=CFTR&Search=Search
9. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989; 245: 1059-1065.
10. European Medicines Agency. [cited 4 October 2015]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002720/human-med-001742.jsp&mid=WC0b01ac058001d124
11. Konstan M, Kerem E, DeBoeck K, et al. Ataluren treatment of patients with nonsense mutation cystic fibrosis. Lancet Respir Med. 2014. doi: 10.1016/S2213-2600(14)70100-6.
12. McColley SA. Ivacaftor therapy for cystic fibrosis. Expert Opinion in Orphan Drugs. 2014. doi: 10.1517/21678707.2014.942220.
13. PubChem Open Chemistry Database. 2015. [cited 2015 Oct 4]. Available from: http://pubchem.ncbi.nlm.nih.gov/compound/Lumacaftor#section=Top.
14. Vertex Drug Information. [cited 17 October 2015]. Available from: http://pi.vrtx.com/files/uspi-lumacaftor-ivacaftor.pdf
15. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England J Med. 2011; 365: 1663-1672.
16. Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013; 187: 1219-1225.
17. De Boeck K, Munck A, Walker S, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. Journal of Cystic Fibrosis. 2014; 13 (Issue 6): 674-680.
18. Moss RB, Flume PA, Elborn JS, et al. On behalf of the VX11-770-110 (KONDUCT) Study Group. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an R117H-CFTR mutation: a double blind, randomised controlled trial. Lancet Respir Med. 2015; 3 (7): 524-533.
19. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA. 2009; 106: 18825-18830.
20. Van Goor F, Hadida S, Groothenhuis PDJ, et al. Correction of the F508del-CFTR protein processing defect in vitro by investigational drug VX-809. Proc Natl Acad Sci USA. 2009; 108: 18843-18848.
21. Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012; 142: 718-724.
22. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809: an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012; 67: 12-18.
23. Boyle MP, Bell SC, Konstan MW, et al. Randomised trial of combined CFTR corrector and potentiator therapy in F508del-CFTR cystic fibrosis. Lancet Respir Med. 2014; 2: 527-538.
24. Wainwright CE, Elborn JS,, Ramsey BW. et al. lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. New England J Med. 2015; 373: 220-231.
25. Sawicki GS, McKone EF, Pasta DJ, et al. Sustained benefit from ivacaftor demonstrated by combining clinical trial and CF patient registry data. Am J Respir Crit Care Med. 2015; 192: 836-842.
26. Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010; 182: 627-632.
27. Jones AM, Barry PJ. Hot off the breath: lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? [cited September 28, 2015]. Available from http://thorax.bmj.com/.
28. Cholon DM, Quinney NL, Fulcher ML, et al. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in Cystic Fibrosis. Sci Transl Med. 2014; 6 (246): 246ra96. doi: 10.1126/scitranslmed.3008680.
29. Veit G, Avramescu RG, Perdomo D, et al. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci Transl Med. 2014; 6 (246): 246ra97. doi: 10.1126/scitranslmed.3008889.
30. Bush A, Simmonds NJ. Hot off the breath: Ive got a cost for the 64 million dollar question. Thorax. 2012; 67: 382-384.
31. OSullivan BP, Orenstein DM, Milla CE. Pricing for orphan drugs: Will the market bear what society cannot? Jama. 2013; 310: 1343-1344.
32. Cohen D, Raftery J. Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding. Bmj. 2014; 348: g1445.